Keynote vs powerpoint 202112/31/2023 ![]() (There is a status bar located in the toolbar of the bottom of the screen that shows video progress.) Be patient this is hard work for your computer’s processor. It’s also recommended to save to your local machine and move it to a shared folder later rather than trying to save a file during conversion across a network or internet connection.ĭepending on the number of slides, size of the file, and power of your computer, converting the PowerPoint to a video can take anywhere from a few seconds to a few minutes to an hour. You’ll be asked to give the file a name, pick a format (MP4 or WMV), and save location. Once you have made your selections for settings, click the “Create Video” button. Note that it has to be the same for each slide and you can’t have varied timings in the same way you can with manual settings. If you don’t want to use recorded timings and narrations, you can set the video to spend a certain amount of time on each slide here. Whether on Mac, iPad, iPhone, or through the web, you can create beautiful. ![]() If you set them in the slide deck, you want to select “Use Recorded Timings and Narrations.” The video will reflect the transitions and any audio you specified in the design of the slides. Apple Keynote is the best app in the Apple iWork suite, thanks to its ease of use. The second dropdown sets how the video should handle timings and narrations. Standard (480p), lowest quality but smallest file size (not as commonly used anymore). ![]() HD (720p), decent quality with smaller file size (good for web playback).Full HD (1080p), high resolution web/digital resolution with a somewhat large file size.Ultra HD (4K), highest quality and largest file size.The top dropdown is for playback quality and resolution. placebo + chemotherapy, followed by adjuvant pembrolizumab vs.The dropdown options in the Export to Video settings relate to playback and timings and narration. KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs.Welcome and introduction, Scientific background and contextįabrice André, Gustave Roussy, Villejuif, France.Neoadjuvant pembro + chemo followed by adjuvant pembro showed a statistically significant and clinically meaningful improvement in EFS compared with neoadjuvant chemotherapy alone in pts with early-stage TNBC. ![]() 0.3%, respectively) immune-mediated AEs of any grade occurred in 43.6% vs. Grade ≥3 treatment-related AE rates were 77.1% in the pembro group and 73.3% in the pbo group (death incidence, 0.5% vs. Pembro showed a favorable trend in OS (HR 0.72 ) follow-up is ongoing. The most common EFS event was distant recurrence, in 60 pts (7.7%) in the pembro group vs. 76.8% (95% CI, 72.2-80.7) in the pbo group median was not reached in either group. At the Madata cutoff (median follow-up, 37.8 mo ), 123 pts (15.7%) in the pembro group and 93 pts (23.8%) in the pbo group had an EFS event, defined as disease progression that precluded definitive surgery, a local/distant recurrence, a second primary cancer, or death from any cause (HR 0.63 P=0.0003). Resultsġ174 pts were randomized to pembro (n=784) or pbo (n=390). Dual primary endpoints are pCR (ypT0/Tis ypN0) and EFS. If you have specific instructions for video playback, note that you can save a PowerPoint as an MP4 or WMV file. (An extra round of proofing never hurt anyone.) Then the file is ready to convert to video. T3/T4), and carboplatin schedule (Q3W vs. Once you have everything just the way you want it, double-check all the slides one more time. Pts were stratified by nodal status (+ vs. After definitive surgery, pts received adjuvant pembro or pbo for 9 cycles or until recurrence or unacceptable toxicity. Pts with previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c N1-2 or T2-4 N0-2 per AJCC) were randomized 2:1 to neoadjuvant pembro 200 mg Q3W or pbo, both given with 4 cycles of paclitaxel + carboplatin, then with 4 cycles of doxorubicin or epirubicin + cyclophosphamide. We present results from a prespecified interim analysis of KEYNOTE-522. In prior interim analyses, pembro + chemo showed a significant improvement in pCR and a favorable trend in EFS. pbo in patients (pts) with early-stage TNBC. placebo (pbo) + chemo followed by adjuvant pembro vs. KEYNOTE-522 ( NCT03036488) is a phase III study of neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. Abstract VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |